Category: Stock Market

Charter Hall Long WALE REIT (ASX: CLW) has announced a quarterly distribution of 6.375 cents per unit, unfranked, to be paid on 15 May 2026. The distribution relates to the quarter ending 31 March 2026.

What did Charter Hall Long WALE REIT report?

• Quarterly distribution of 6.375 cents per unit, unfranked
• Ex-dividend date: 30 March 2026
• Record date: 31 March 2026
• Payment date: 15 May 2026
• Distribution Reinvestment Plan (DRP) available with a 1% discount

What else do investors need to know?

The DRP allows investors to reinvest their distributions at a 1% discount to the average daily volume weighted average price between 7 and 20 April 2026. The last date to elect participation in the DRP is 1 April 2026. DRP pricing details will be confirmed in a separate announcement on or around 15 May 2026.

The distribution is fully unfranked and not designated as conduit foreign income. Investors who do not elect to participate in the DRP will receive their distribution as a standard cash payment.

What’s next for Charter Hall Long WALE REIT?

Charter Hall Long WALE REIT continues to provide regular income to its unit holders through quarterly distributions. Investors may review their DRP options ahead of the April 1 deadline, while details of the DRP price will be provided closer to the payment date.

The REIT remains focused on maintaining a strong and predictable income stream for investors, underpinned by a diversified portfolio of properties with long lease terms.

Charter Hall Long WALE REIT share price snapshot

Over the past 12 months, Charter Hall Long WALE REIT shares have declined 6%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 9% over the same period.

View Original Announcement

The post Charter Hall Long WALE REIT declares March 2026 distribution and DRP update appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Thursday
• Here are the top 10 ASX 200 shares today
• Markets brace for the next shock as global tensions flare up
• Woodside Energy Group appoints Liz Westcott as CEO
• Sims flags stronger FY26 earnings on robust metals and tech demand

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Shares in Racura Oncology Ltd (ASX: RAC) have jumped more than 10% in early trade after the company announced the successful first dosing of a patient in Hong Kong with its RC220 cancer compound.

The company said in a statement to the ASX that the patient was the third to be dosed with the compound, but the first at the Hong Kong Site.

Good early signs

Racura said no vein inflammation or other adverse events were reported following the dosing, and to date, no dose-limiting toxicities have been observed in any of the three patients dosed.

The company added:

Dosing of the third patient also completes recruitment of the first trial cohort. In accordance with the trial protocol, the Safety Review Committee (SRC) will review all accumulated safety data collected from the three patients. Subject to SRC review and clearance, the trial will then progress to the next planned RC220 dose level of 80 mg/m2 using the updated trial protocol announced 11 February 2026.

Racura Chief Executive Officer Dr Daniel Tillett said on Thursday:

The safe dosing of the third patient in our RC220 solid tumour trial in Hong Kong and recruitment of the first dose escalation cohort is an important milestone for Racura Oncology. We are grateful to all the patients, investigators, and clinical teams who have made this trial possible and we look forward to treating patients on the updated protocol.

Stage 1 of the RC220 trial will be carried out across Australia, Hong Kong, and South Korea, and involves ascending doses “to determine the safety, tolerability, pharmacokinetics, and maximum tolerated combined dose of RC220 in combination with doxorubicin in up to 33 patients”.

After interim analysis of the data, another 20 patients will be administered the compound to test for further safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals, Racura said.

Multiple uses being examined

Racura said in its statement to the ASX that RC220 was being tested to address the high unmet needs of patients across multiple cancer indications with a Phase 3 clinical program in acute myeloid leukemia, a Phase 1a/b program in lung cancer, and the trial mentioned previously, which aims to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.

The ASX biotech’s shares traded as high as $2.73 on the news, up 14.7%, before settling back to be 8.8% higher at $2.57.

Racura was valued at $433 million at the close of trade on Wednesday.

The post Which ASX biotech’s shares have jumped more than 10% on positive clinical trial news? appeared first on The Motley Fool Australia.

More reading

• Down 87% since Friday, why is this ASX 300 healthcare stock sliding again today?
• Charter Hall Long WALE REIT declares March 2026 distribution and DRP update
• If a 30-year-old invests $500 a month in ASX stocks, here’s what they could have by retirement
• 2 great ASX 200 blue-chip shares I’d buy right now
• Why Boss Energy shares are falling despite positive uranium update

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX stocks could be the ticket for younger investors to become a lot wealthier over time. Investing just $500 per month can compound into a very pleasing figure by retirement.

It’s easy to underestimate how powerful compounding can be. One of the world’s greatest ever minds, Albert Einstein, once supposedly said:

Compound interest is the most powerful force in the universe. Compound interest is the eighth wonder of the world. He who understands it, earns it; he who doesn’t pays it.

Someone who is 30 now may have 40 years to grow their nest egg until retirement age. People can retire earlier than 70 if they’re able and willing to.

How much could someone’s wealth actually grow? Let’s take a look.

The long-term goal

Growing wealth towards retirement can take a while, but it’s very rewarding to see it grow over time. Planting a sapling (in the right place) will become a sizeable tree – but we need to be patient.

I think it’s a great move to regularly invest in ASX stocks. The ASX share market has returned an average of 10% per year over the ultra-long-term. That level of return is very satisfactory.

For example, if $5,000 were invested today and it grew by an average of 10% per year for 40 years, it’d become $226,296.

It’s hard to say what a good figure will be for retirement in 40 years from now, but it’ll probably need to be more than $226,000.

In the current inflationary environment, it could be harder to save $500 per month. However a household does it, to invest we need to spend less than we earn to unlock those monthly savings.

If someone invested $500 per month and it grew by 10% per year for 40 years, it’d become $2.65 million. That’d be a really nice level of wealth, in my eyes. Remember, it assumes investing $500 throughout the process. Being able to invest more during some later years will help it become much larger.

How can someone accelerate reaching retirement?

I’d understand wanting to retire earlier than 70, and there are two main ways to do so.

Firstly, someone can invest more each month, though that’s easier said than done.

Second, we can choose investments that deliver higher returns. For example, if an investment returned 12% per year, then investing $500 per month would grow to around $2.6 million in 35 years – seeing stronger returns could shave 5 years off retirement age.

I’d look at ASX growth stocks and international shares as ideas that could outperform the wider ASX share market. One exchange-traded fund (ETF) to consider is Vanguard MSCI Index International Shares ETF (ASX: VGS). There are plenty of great ASX growth stocks at good prices right now.

The post If a 30-year-old invests $500 a month in ASX stocks, here’s what they could have by retirement appeared first on The Motley Fool Australia.

More reading

• Why I’d buy VGS and these Vanguard ETFs right now
• New to investing? Start with ASX ETFs and quality ASX stocks
• 5 fantastic ASX ETFs to buy and hold for five years
• Look long-term with these 3 ASX ETFs
• Just 3 ASX ETFs could build a lazy Australian millionaire portfolio

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Vanguard Msci Index International Shares ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

There is a lot of market volatility right now, giving investors plenty to think about. I think it would be a good call to invest in S&P/ASX 200 Index (ASX: XJO) blue-chip shares that can deliver solid profit growth and outperform the market.

I’m still optimistic about what the long-term holds for Australia and the ASX share market as a whole. But the short-term can throw up some issues.

If I were looking for which ASX 200 blue-chip shares to buy, the following names could be some of the best ones to own over the next year and the rest of the decade.

Coles Group Ltd (ASX: COL)

Coles is the second-largest supermarket business in Australia, and it continues to grow in size through both total sales and its supermarket network.

The ASX 200 blue-chip share delivered an impressive first-half FY26 report, with total revenue growth of 3.6% and underlying net profit growth of 12.5%.

Sales growth remained pleasing in the first seven weeks of the second half of FY26, with supermarket revenue up 3.7% (5.3% excluding tobacco).

Coles has attracted customers with its wider range of own-brand products and exclusive Coles items, while also offering convenience and improved value.

I don’t know how this new period of inflation will play out, but if it leads to higher food prices, then Coles may be able to pass on price rises again. But, there’ll probably be widespread attention on its gross profit margin.

However, its growing scale and new, advanced warehouses should help the company improve its bottom line in the coming years.

Based on CommSec’s forecasts, the ASX 200 blue-chip share is trading at 23x FY26’s estimated earnings, with a grossed-up dividend yield of 5.2% including franking credits.

Wesfarmers Ltd (ASX: WES)

Wesfarmers owns a number of leading Australian businesses, including Bunnings, Kmart, Officeworks, and Priceline. Other parts of its business include Target, InstantScripts, WesCEF (chemicals, energy and fertilisers), an industrial and safety division, and more.

I like the diversification that Wesfarmers has – it’s not too exposed to one area and has the ability to invest in whatever area of its current business (or a new business) it needs to generate the best profit growth for shareholders.

Kmart and Bunnings have continued to deliver sales growth in both HY26 and at the start of the second half of FY26, which I think is an important driver of future value for investors. Wesfarmers’ two main businesses offer customers great value products, which could help them perform and gain market share during this period of potential higher inflation.

Wesfarmers’ rising profit margins and high return on equity (ROE) make sales growth very rewarding for the business.

The ASX 200 blue-chip share continues to expand its growth avenues, such as selling Anko products in the Philippines, which could become increasingly useful to the overall Wesfarmers picture.

According to the CommSec forecast, the Wesfarmers share price is valued at under 30x FY26’s estimated earnings, with a grossed-up dividend yield of 4.1% including franking credits.

The post 2 great ASX 200 blue-chip shares I’d buy right now appeared first on The Motley Fool Australia.

More reading

• How are Australia’s biggest blue-chip stocks performing in 2026?
• Why these ASX shares could be buys in today’s volatile market
• Should I invest $5,000 in Coles shares now?
• Woolworths shares are storming ahead of Coles this year: Are the supermarket giants a buy, sell, or hold?
• The ideal Australian stocks to buy and hold forever

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Wesfarmers. The Motley Fool Australia has recommended Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Boss Energy Ltd (ASX: BOE) shares are on the slide on Thursday morning.

At the time of writing, the ASX uranium stock is down 4.5% to $1.56.

Why are Boss Energy shares falling today?

The company’s shares are falling today after a market selloff offset the release of a positive announcement relating to its Gould’s Dam and Jason’s Deposit satellite uranium deposits near the Honeymoon operation.

According to the release, Boss Energy has updated the mineral resource estimate for Gould’s Dam to 38.7Mt at 388ppm U3O8 for 33.1Mlbs of contained U3O8. This represents a 30% increase in total contained uranium from the previous estimate.

The company also updated the mineral resource estimate for Jason’s Deposit to 13.3Mt at 410ppm U3O8 for 12.0Mlbs of uranium. That is up 9% from the previous estimate.

Development pathway advancing

Boss advised that the development pathway for both deposits has accelerated over the past six months, with baseline and technical studies for permitting applications being advanced.

The company is targeting the commencement of state and federal approvals processes in the second half of calendar year 2026.

However, Boss added that the timeframe from initial applications to the granting of a mining lease is expected to take up to 18 to 24 months, followed by a further six to 12 months for Program for Environment Protection and Rehabilitation approval.

So, if everything goes to plan, it will still be some time before these deposits contribute to the Honeymoon project.

Boss Energy’s managing director, Matthew Dusci, was pleased with the progress. He said:

Over the past six months, the Company has initiated several strategic programs aimed at unlocking shareholder value. One of these is aimed at progressing the value realisation of Gould’s Dam and Jason’s Deposit located close to the Honeymoon Operation. The updated Mineral Resource Estimates for Gould’s Dam and Jason’s Deposit incorporate additional drilling and an improved understanding of geology and mineralisation controls derived from the Honeymoon deposit.

This work highlights the significance of these deposits, with Gould’s Dam and Jason’s Deposit hosting 33Mlbs and 12Mlbs of uranium, respectively, with mineralisation at both deposits remaining open. Further drilling programs are planned to commence in the second half of this calendar year to continue to extend both resources.

Commenting on the impact on the New Feasibility Study for Honeymoon, Dusci adds:

The wide-spaced wellfield design being advanced as part of the New Feasibility Study at Honeymoon is also expected to be directly applicable to these satellite deposits. If successful, this approach has the potential to deliver a high conversion of resource to wellfield mining inventory through cost-efficient extraction. Early indications suggest that both deposits could be material production sources of uranium in the future, leveraging the existing infrastructure at the Honeymoon Operation.

The post Why Boss Energy shares are falling despite positive uranium update appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• Here are the top 10 ASX 200 shares today
• Why ASX uranium shares like Paladin and Boss Energy could be set to rocket
• One uranium stock to buy and one to sell, according to Macquarie
• Why Boss Energy, Lindian, Magellan, and New Hope shares are rising today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Core Lithium Ltd (ASX: CXO) shares have returned from their trading halt and are dropping.

At the time of writing, the lithium miner’s shares are down 4.5% to 21 cents.

Why are Core Lithium shares falling?

The company’s shares are falling today after it completed a $120 million institutional placement at a modest 4.5% discount of 21 cents per new share.

Management notes that the Placement was strongly supported by a number of new and existing high‑quality institutional, sophisticated, and professional investors.

This complements a US$120 million (A$170 million) strategic funding from Glencore Australia, InfraVia, and the Nebari Natural Resources Credit Fund.

Why is it raising funds?

On Wednesday, Core Lithium announced a positive final investment decision (FID) for the restart of the Finniss Lithium Project.

It notes that this followed the completion of a comprehensive restart plan, updated mine planning, Front-End Engineering and Design work, and refined operating strategies to reposition Finniss as a lower‑cost, long‑life lithium operation.

The company advised that the board approval reflects the improved economic metrics of the restart, as well as confidence in delivering sustained production supported by a de-risked execution plan.

The combined funding package allows Core Lithium to immediately commence mobilisation, early works, and BP33 development.

First concentrate production is expected during the September quarter of 2026.

Compelling economics

It isn’t hard to see why the FID was positive.

Core Lithium revealed that the project delivers compelling economics, with a pre‑tax net present value of A$1.1 billion and free cash flow generation of A$1.7 billion.

This is being underpinned by competitive unit operating costs of A$762 per tonne and a conservative long‑term spodumene concentrate price assumption of US$1,500 per tonne. This compares to the current spot price of ~US$2,200 per tonne.

Commenting on institutional placement and its restart, Core Lithium’s managing director, Paul Brown, said:

The strong support we have received through this equity raising is a clear endorsement of Core’s restart strategy and the long-term value of the Finniss Operation. Combined with the strategic funding from Glencore, InfraVia and Nebari, this places Core in a fully funded position to execute the restart in line with the FID.

This outcome reflects the confidence investors have in our disciplined planning, improved project economics and the capability of our team to deliver a safe, staged and efficient return to production. With funding now secured, we can move immediately into mobilisation, early works and development activities to position Finniss for first concentrate production in the September quarter of 2026.

The post Core Lithium shares tumble after $120m capital raising for Finniss restart appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Thursday
• Why this ASX lithium stock requested a trading halt today
• Why these 3 ASX lithium shares are charging higher today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Working out whether your superannuation is on track depends entirely on your current age and what type of retirement you’re aiming for.

A comfortable retirement, which is defined as allowing retirees to maintain a good standard of living, is expected to cost approximately $54,840 per year for individuals and $77,375 per year for couples.

To support that retirement lifestyle, ASFA estimates that Australians need a super balance of roughly $630,000 as a single and $730,000 as a couple by age 67. 

The figures also assume you own your home outright and that you’re receiving the age pension.

Is my superannuation on track?

Using ASFA’s calculator, I’ve crunched the numbers and worked out what superannuation balance you need to stay on track for a comfortable retirement.

At age 40, you should have close to $178,000 in superannuation. This needs to climb to $239,000 by age 45.

At age 50, you should have close to $313,500 in superannuation and by age 55, it should be closer to $399,000 in superannuation.

At age 60, you should have close to $496,500 in superannuation. This needs to hike to $604,500 in superannuation by age 65 in order to remain on track.

Help! I’m behind. What do I do now? 

If your superannuation balance is lower than what you should have at your age, you’re not alone. And there are things you can do to catch up before it’s too late.

The easiest way to get back on track is by reviewing your current superannuation fund. Is your fund performing well and in line with market expectations or a benchmark such as the S&P/ASX 200 Index (ASX: XJO)? The difference between a poor-performing fund and a top-performing one can be the difference between scraping by in retirement and living comfortably. 

Then check that your fund’s risk appetite aligns with your own. Putting your money into the wrong type of fund can quickly chip away at your balance. It makes sense to be conservative later on in life when you’re approaching retirement, but being too conservative too early means you’ll lose out on the potential for more growth. 

Next, you need to add extra concessional or non-concessional contributions, whether by salary sacrificing or after-tax contributions (within your annual limits). There’s no sense adding money to your superannuation fund if it means you’ll struggle to make it to payday. But the power of compounding returns means that the more money you can invest when you’re younger, the more impact it will have on your final balance.

Lastly, take advantage of any government initiatives available to you. There’s the downsizer contributions rule, the bring-forward rule, the government co-contribution rule, and many others. These can help boost your balance just a little bit further. 

The post Is your superannuation on track? Here’s what to do if you’re falling behind appeared first on The Motley Fool Australia.

More reading

• Down 87% since Friday, why is this ASX 300 healthcare stock sliding again today?
• Charter Hall Long WALE REIT declares March 2026 distribution and DRP update
• Which ASX biotech’s shares have jumped more than 10% on positive clinical trial news?
• If a 30-year-old invests $500 a month in ASX stocks, here’s what they could have by retirement
• 2 great ASX 200 blue-chip shares I’d buy right now

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The rare earths industry has been booming over the past 12 months because of strong demand and tight supply.

The good news is that these conditions are expected to remain for the foreseeable future, which could make it worth having some exposure to ASX rare earths stocks.

The team at Wilsons has been looking at this side of the market and is feeling very positive. It said:

The rare earth market is benefiting from a powerful combination of structural demand growth, constrained supply and increasing policy support for ex-China supply chains. These dynamics are expected to support elevated rare earth prices while also strengthening demand for, and the pricing outcomes of, Western supply in particular.

But which shares could be buys for rare earths exposure? Let’s take a look at three that Canaccord Genuity is bullish on, courtesy of Wilsons. They are as follows:

Brazilian Rare Earths Ltd (ASX: BRE)

Canaccord Genuity thinks investors with a high tolerance for risk should look at this rare earths developer.

It has put a speculative buy rating and $8.00 price target on this Brazil-focused ASX rare earths stock. Based on its current share price of $4.70, this implies potential upside of 70% for investors over the next 12 months. It said:

Highest grades we have come across at the Monte Alto discovery in Brazil – partnership with Carester, upcoming Resource/ Scoping for integrated oxide production + bauxite spinout offer potential catalysts.

Iluka Resources Ltd (ASX: ILU)

Another ASX rare earths stock that is highly rated is Iluka. Although its mineral sands business is weighing on its performance, its exposure to rare earths with the Eneabba project is seen as a reason to buy.

Canaccord Genuity has a buy rating and $6.55 price target. However, this is largely in line with where its shares currently trade.

Commenting on the stock, the broker said:

Mineral sands business suffering from structural issues, but Eneabba provides medium-term exposure + a possible beneficiary of Australian Critical Minerals Reserve floor pricing.

Meteoric Resources NL (ASX: MEI)

A final ASX rare earths stock that gets the thumbs up from the broker is Meteoric Resources.

Canaccord Genuity has put a speculative buy rating and 40 cents price target on its shares. This is more than double its current share price.

Commenting on the Brazil-based developer, it said:

Low capex/low cost IAC development project in Brazil approaching major milestones (BFS/approvals/ funding/FID) in mid’26.

The post Top broker names 3 ASX rare earths stocks to buy appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• Why Brazilian Rare Earths, Lynas, Macquarie Technology, and Ora Banda shares are pushing higher today
• 5 of the best ASX 200 stocks to buy and hold in February revealed
• Here are the top 10 ASX 200 shares today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Hitting your first $100,000 in retirement savings is a big milestone.

But the next goal, reaching $1 million, can feel a lot further away.

The good news is that once you’ve built that initial base, the process often becomes easier. Compounding starts to do more of the heavy lifting, and small improvements in your strategy can make a meaningful difference over time.

Here’s how I’d think about turning $100,000 into $1 million.

1. Let compounding do the heavy lifting

If there’s one concept that matters more than anything else, it’s compounding.

Once you have $100,000 invested, your money can start generating returns on top of returns.

For example, if you were able to achieve an average return of 9% per year, that $100,000 would grow to around $560,000 over 20 years without adding another dollar.

That still falls short of the $1 million retirement portfolio target, but it highlights just how quickly your money can grow.

In my view, the key here is staying invested. Trying to time the market or jumping in and out of positions can disrupt compounding and make the journey much harder.

2. Add consistently over time

Compounding works best when it’s paired with regular contributions.

Even modest additions can have a big impact when combined with long-term returns.

Let’s say you added $1,000 per month and earned that same 9% return. Over 20 years, your portfolio could grow beyond $1 million.

In fact, it would take a total of 18 years to reach our retirement target.

That’s the combination that tends to deliver results over time. A solid starting base, consistent contributions, and time.

It’s also a strategy that removes the pressure to pick the perfect stock. Instead, you’re steadily building wealth regardless of short-term market movements.

3. Focus on quality investments

The returns you earn matter.

While no returns are guaranteed, investing in high-quality ASX shares or broad-based exchange-traded funds (ETFs) can improve your chances of achieving strong long-term returns.

That might include market-leading companies with durable earnings, businesses that can grow over time, and diversified ETFs that track large sections of the market.

Examples include Commonwealth Bank of Australia (ASX: CBA), ResMed Inc (ASX: RMD), Macquarie Group Ltd (ASX: MQG), and iShares S&P 500 ETF (ASX: IVV).

The goal isn’t to chase the highest possible return. It’s to find investments you can hold through cycles without feeling the need to sell.

In my experience, consistency beats complexity here.

Bringing it all together

Building a $1 million retirement portfolio from $100,000 isn’t about one big decision. It’s about a combination of time, discipline, and a simple plan.

Compounding gets you started. Contributions keep you moving forward. And quality investments help you stay on track.

Miss one of those, and the journey becomes harder. Get all three working together, and the path becomes much more achievable.

Foolish Takeaway

Going from $100,000 to $1 million might sound daunting, but it’s often more straightforward than people think.

With time, regular investing, and a focus on quality, that next milestone is well within reach.

For me, the key is simple. Stay invested, keep adding, and let compounding do its job.

The post 3 ways to get from $100,000 to $1 million in retirement savings appeared first on The Motley Fool Australia.

More reading

• Are these the smartest ASX tech stocks to buy now with $2,000?
• Bell Potter just put a buy rating on this exciting small-cap ASX stock
• How are Australia’s biggest blue-chip stocks performing in 2026?
• Where to invest $20,000 for dividend income on the ASX
• Portfolio strategies for 2 potential Middle East scenarios – Expert

Motley Fool contributor Grace Alvino has positions in Commonwealth Bank Of Australia. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group, ResMed, and iShares S&P 500 ETF. The Motley Fool Australia has positions in and has recommended Macquarie Group and ResMed. The Motley Fool Australia has recommended iShares S&P 500 ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

It hasn’t been a great year for many ASX tech stocks.

Some of the market’s highest-quality names have been sold off heavily, with investors worried about valuations, interest rates, and the impact of artificial intelligence (AI) disruption.

But when I see great businesses down 40% to 60%, I start paying attention.

Three that stand out to me as smart buys for investors with $2,000 are below.

Pro Medicus Ltd (ASX: PME)

Pro Medicus has fallen roughly 60% from its highs, which is a big move for a company that’s rarely looked cheap.

What I find interesting is that the core story hasn’t really changed.

This is still a global leader in medical imaging software, with long-term contracts, high margins, and a growing presence in the US healthcare system. 

Furthermore, management has spoken at length about why it believes AI will benefit its business, not disrupt it.

In my view, businesses like this don’t often go on sale. And when they do, it’s usually because of broader market sentiment rather than something fundamentally broken.

It still won’t be the cheapest stock on traditional metrics. But I think quality rarely is.

Xero Ltd (ASX: XRO)

Xero is also down around 60% from its peak, which feels significant for a business of its scale.

What I like here is the combination of growth and stickiness. Once small businesses adopt accounting software, they tend to stay. That creates recurring revenue and strong customer retention.

On top of that, Xero still has a long runway for growth globally. Management estimates that its total addressable market is $100 billion globally across accounting, payments, and payroll.

To me, the key question isn’t whether Xero can grow. It’s how fast, and at what margins.

If management continues to improve profitability while expanding internationally, I think the current share price weakness could look like an incredible opportunity in hindsight.

TechnologyOne Ltd (ASX: TNE)

TechnologyOne hasn’t fallen as much as the others, down around 40%, but it’s still a meaningful pullback.

This is probably the most predictable of the three ASX tech stocks. It provides enterprise software to government and education sectors, with long-term contracts and high recurring revenue.

What stands out to me is its consistency. Revenue growth, margins, and returns have been steadily improving over time.

It’s not trying to dominate the world like some tech companies. It’s executing well in its niche.

And sometimes, that’s exactly what you want.

Foolish takeaway

Pro Medicus, Xero, and TechnologyOne aren’t risk-free investments.

But after significant share price declines, I think the risk-reward profile has improved significantly.

For me, this is the kind of setup I like. Strong businesses, long-term growth potential, and a market that’s giving you a second chance to buy them at a lower price.

They may not be the only ASX tech stocks to consider, but right now, they could be some of the smartest.

The post Are these the smartest ASX tech stocks to buy now with $2,000? appeared first on The Motley Fool Australia.

More reading

• 3 ASX healthcare stocks tipped to soar over 100% higher this year
• Xero shares rise again. Is this the start of a turnaround?
• Top brokers name 3 ASX shares to buy today
• Why Brightstar, EQ Resources, Novonix, and Pro Medicus shares are falling today
• The ideal Australian stocks to buy and hold forever

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Technology One and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool Australia has recommended Pro Medicus and Technology One. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.